NYSE: SYKStryker Corp Stock
$339.13-2.92 (-0.85%)
Updated Apr 15, 2024
SYK Price
$339.13
Fair Value Price
N/A
Market Cap
$128.96B
52 Week Low
$249.98
52 Week High
$361.41
P/E
40.66x
P/B
6.94x
P/S
5.55x
PEG
2.24x
Dividend Yield
0.91%
Revenue
$20.50B
Earnings
$3.17B
Gross Margin
63.7%
Operating Margin
17.92%
Profit Margin
15.4%
Debt to Equity
1.15
Operating Cash Flow
$4B
Beta
1.05
Next Earnings
Apr 30, 2024
Ex-Dividend
Mar 27, 2024
Next Dividend
Apr 30, 2024
SYK Overview
Stryker Corporation is a medical technology company that operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. It also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company was founded in 1941 and is headquartered in Kalamazoo, MI.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SYK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SYK ($339.13) is trading above its intrinsic value of $98.80, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SYK is good value based on its earnings relative to its share price (40.66x), compared to the US market average (41.94x)
P/E vs Market Valuation
SYK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more SYK due diligence checks available for Premium users.
Be the first to know about important SYK news, forecast changes, insider trades & much more!
SYK News
Valuation
SYK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
40.66x
Industry
29.46x
Market
41.94x
SYK is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
SYK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
SYK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.94x
Industry
3.71x
SYK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SYK price to earnings growth (PEG)
For valuing profitable companies with growth potential
SYK is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
SYK's financial health
Profit margin
Revenue
$5.8B
Net Income
$1.1B
Profit Margin
19.7%
SYK's Earnings (EBIT) of $3.67B... subscribe to Premium to read more.
Interest Coverage Financials
SYK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$39.9B
Liabilities
$21.3B
Debt to equity
1.15
SYK's short-term assets ($12.52B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SYK's long-term liabilities ($13.40B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SYK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SYK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.5B
Investing
-$152.0M
Financing
-$286.0M
SYK's operating cash flow ($3.71B)... subscribe to Premium to read more.
Debt Coverage Financials
SYK vs Medical Device Stocks
Stryker Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.